Archive | 3CTN RSS for this section

3CTN annual report

The 3CTN 2018/19 annual report can be downloaded from

Pediatric specific information can be found on pages 2 and 6. Other topics include:

  • future 3CTN priorities
  • impact assessment
  • site specific data for those sites participating in 3CTN
  • patient involvement
  • financial reporting

3CTN Release: 2017-2018 Annual Report

The report summarizes the accomplishments of the 3CTN cancer centres and represents the culmination of its initial four year strategic plan spanning 2014-2018. Throughout its pages you will see many examples of how 3CTN has established a sustained framework for supporting Canada’s academic cancer clinical trials environment and set a foundation for work to follow over the next four years.

You can view and download the 2017-2018 Annual Report here.

How are you celebrating International Clinical Trials Day (May 20th)? #ICTD2018

From 3CTN:

Your site’s staff work hard all year to help patients and families access important clinical trials and advance cancer care in Canada.

To celebrate International Clinical Trials Day (ICDT) on May 20, we hope all 3CTN sites are in the process of planning ICTD activities to mark this special day.

Join us in showing your support online with the Hashtags #ICTD2018 #3CTN and share your site stories to the 3CTN Network.

Connect with staff and staff supporters in recognizing clinical research professionals at your site.

After the events, include a brief message of your celebrations, attach any memorable photos and send to to be featured on our upcoming National Newsletter!

Don’t miss out on the opportunity to celebrate #ICTD2018!


Celebrating International Clinical Trials Day 2018
Growing Cancer Clinical Research Together
#ICTD2018 #3CTN #AskMeCampaign

Contact Us
For inquiries please contact: or call 1-866-678-6427

Canadian Cancer Clinical Trials Network, MaRS Centre, 661 University Ave,
Suite 510 Toronto, Ontario Canada M5G 0A3

Did you know that 27 pediatric oncology studies have been added to the 3CTN portfolio since April 2014? Follow the weekly C17 Sosido Digest for our new study focus postings, like the one below.

Each pediatric hem/onc site is sent a reporting worksheet every three months.  This sheet shows all 3CTN eligible pediatric studies, or you can search the 3CTN Portfolio Directly at:

If you notice a study missing from the portfolio, please contact us.  The eligibility criteria are:

  • a cancer intervention clinical trial
  • an academic clinical trial (if a NOL is required, a non-industry organization/institute must be sponsor)
  • open at more that one Canadian site – note that the second site can be an adult oncology program


3CTN Network Pulse Newsletter – April 2016 ( Includes resources for Public Patient Involvement in clinical trials

Taken from the April 2016 3CTN Network Pulse Newsletter:

Public and Patient Involvement
3CTN Continues to Support PPI Site-Level Activities

A key recommendation of the SAB’s 18 month review was for the 3CTN CC and the Lay Representative Advisory Committee (LRAC) to continue to support the roll out of PPI activities and roles across Network sites. To date, we have made the following tools and documents available to sites:

  • 3CTN PPI Website, which includes:
    • PPI Toolkit for Site Staff
    • PPI Toolkit for Lay Representatives
    • PPI News – Updated Monthly and has open call to sites to share their local PPI activities and events
  • 3CTN Guide to PPI
  • Framework of Community Representation on Health Research Committees


Further to these tools, this month 3CTN is releasing the new “PPI Reference Tool” and introducing the “Ask Me” Ambassador PPI role. Each of these new tools are intended to provide sites with concrete ways to incorporate PPI activities locally, especially for sites that might be struggling with way to adapt PPI to their local needs or goals.

  • The PPI Reference Tool:This new tool has been added to the PPI Toolkit for Sites and is a “Cole’s notes” walkthrough of all the steps involved in developing and implementing a PPI role on local institutional committees. This tool also acts as across reference guide between the “PPI Framework” and the 3CTN PPI Guide so that site staff can quickly navigate relevant document sections that may help with each step of implementing a PPI role.
  • Ask Me Ambassador PPI Role: Sites that are currently in the process of their local “Ask Me” roll out may wish to add the Ask Me Ambassador role to the roll out plan. This PPI role is covered in detail as part of the new PPI Reference Tool and represents a great opportunity for sites to involve local patients that may wish to act as trial advocates or peer mentors for new patients that are considering trial participation.

The 3CTN CC and LRAC continue to increase the number of tools available to sites to implement PPI activities which will allow the Network to leverage the positive impact of PPI on recruitment and other clinical trial activities. With this month’s new tools Network sites can unlock the value of PPI locally and then share their local success stories with the 3CTN CC.

C17 is measuring academic clinical trial accruals in Canada as part of 3CTN. If your study is eligible and not on the portfolio, please contact C17.

3CTN is an initiative to increase participation in academic oncology clinical trials in Canada (  As part of this project, C17 is tracking enrollment on pediatric clinical trials that are eligible for the 3CTN portfolio, and we would like to ensure that we have included all eligible studies.  We are aware of studies that we sponsor (e.g., COG, TACL),  but for other studies we rely on information from you, the researchers.

Are you aware of a study pediatric oncology study that meets the criteria below, please contact Leah in the C17 Council office (

  • intervention study
  • open at more than one site in Canada (second site does not need to be a pediatric oncology/hematology centre)
  • not sponsored by industry

Note that a CTA is not required for eligibility, but a study would have to be listed on to go on the 3CTN portfolio.



3CTN Network Pulse March 2016 Newsletter available at

The 3CTN Network Pulse Newsletter (March 2016) can be viewed here..  Topics covered include:

  • Recruitment is on the rise
  • Framework of Community Representation on Health Research Committees
  • 3CTN’s 18 Month Review
  • Feature Trial– OZM-053 Title: Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
  • All Network sites are reminded that they must complete CTRNet Registration for their sites by March 31st, 2016
  • What’s new with EDGE
  • Whats New? Key Dates



Canadian Tumour Repository Network (CTRNet): update on 3CTN collaboration to develop standardized clinical trial biospecimen collection processes

The 3CTN is a pan-Canadian initiative to improve the efficiency and quality of clinical trials in Canada in order to ensure that Canadians with cancer and those at risk will have the best available cancer treatments. 3CTN and The Canadian Tumour Repository Network (CTRNet) are working together to help ensure there is access to adequate numbers of high-quality biospecimens across their network.

As part of the establishment phase, 3CTN wants to provide education on research biospecimen handling for at least one 3CTN team member per site to ensure there is access to adequate numbers of high-quality biospecimens through standardization of  clinical trial biospecimen collection processes. 3CTN is collaborating with the UBC Office of Biobank Education and Research (OBER) to assist research sites in assessing their clinical trial biospecimen collection practices. This affects any site that collects samples in the context of clinical trials, and not just those sites with a formal biobank.

More information regarding the education initiative will be circulated to the C17 sites.

To learn more about CTRNet, visit


3CTN December newsletter available: AYA trial and national recruitment updates

The 3CTN December newsletter is available.  To be redirected to the newsletter, click here.

3CTN Supporting Development of a ALL trial in the AYA Population

Adolescents and Young Adults (AYA) diagnosed with cancer have a unique set of challenges throughout their cancer journey and historically there have been limited formal clinical trials available to this population. To help support research in this important yet underserved segment of the Canadian cancer population, 3CTN is facilitating the development of a new clinical trial for the AYA population. The process began in the spring of 2015 with the release of a request for applications, which asked AYA researchers to submit clinical trial proposals.

Over the past few months, through a formal review and selection process, one project proposal for a trial in Acute Lymphoblastic Leukemia (ALL) was ultimately selected. On November 30 2015, 3CTN and our collaborators* held a workshop in Montreal, Quebec focused on developing this proposed pan-Canadian clinical trial. The workshop brought together principal investigators and site research staff from many Canadian pediatric and adult cancer centres with the common goal of launching a trial to address current knowledge gaps in AYA ALL therapy. Topics covered at the workshop included prioritizing the clinical needs of AYA ALL patients, identification of potential new agents and the status of the relevant diagnostic tests that will be required for a trial. A smaller working group will now focus on designing a draft protocol for a study to open within the next year. Clinical trials targeted to AYA with ALL will ultimately improve the standard of care and health outcomes for this population.

After the workshop, 3CTN provided a satisfaction survey and invited participants to provide feedback on the workshop. Nearly 70 per cent of attendees responded to the survey and indicated that overall, they were pleased with the workshop and that it met its stated goals and objectives.

The final goal of this AYA ALL trial development process will be a clinical trial in which Network centres can participate via the 3CTN Portfolio. Collectively our Network’s involvement may help decrease the knowledge gap in therapy for AYA Canadians diagnosed with ALL.